Energy investors are making a big mistake… They're "bottom fishing" in the major oil and gas stocks… trying to catch the bottom. This, of course, is a bad idea. Energy stocks have been crashing this year. But expectations are still high. History tells us this kind of bottom fishing won't end well. The smart move is to wait for a better entry point before getting in. Let me explain… Bottom fishing can be hard to avoid… Instead of buying what's going up – what's in an uptrend – investors have a habit of buying what's falling. It seems like a smart move… You're buying what's cheap. You're buying what no one else wants. And heck, if you get lucky, you've got a remarkable success story to brag about. But those success stories are rare… And trying to catch one can be costly.
Top Energy Stocks To Own For 2018: PDC Energy, Inc.(PDCE)
- [By Ben Levisohn]
Goldman Sachs analyst Brian Singer and team contend that EOG Resources (EOG), Diamondback Energy (FANG), PDC Energy (PDCE), Pioneer Natural Resources (PXD), and RSP Permian (RSPP) can benefit from greater productivity. They explain:
- [By Ben Levisohn]
Names which screen well on a combination of attractive valuation and equitized capital structure, include Outperform rated Apache, Anadarko Petroleum,Gulfport Energy as well as Market Perform rated QEP Resources (QEP) and PDC Energy (PDCE).
Top Energy Stocks To Own For 2018: National Fuel Gas Company(NFG)
- [By Lee Jackson]
These companies also reported insider selling last week: National Fuel Gas Co. (NYSE: NFG), Prologis Inc. (NYSE: PLD), Realty Income Corp. (NYSE: O), Ulta Beauty Inc. (NASDAQ: ULTA) and Versartis Inc. (NASDAQ: VSAR).
Top Energy Stocks To Own For 2018: Valeant Pharmaceuticals International Inc(VRX)
- [By Chris Lange]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) made waves early on Tuesday after the company offered a plethora of announcements. First the company gave an update on its late-stage psoriasis trial. Along with this success, Valeant reported the sale of a couple of its business segments, bringing in a sizable amount of cash.
- [By Kumar Abhishek]
Shares of specialty pharma company Valeant Pharmaceuticals Intl Inc(NYSE:VRX)have tanked more than 20% in last two trading sessions, breaching the support from the 50 day SMA, after the Laval,Quebec-based company reported its Q4 and FY 2016 earnings on Tuesday, before the market opened. While the earnings itself were better than expected, the guidance for FY 2017 didn’t go down well with investors and wall street, earning the company multiple price target cuts. Valeant reported an adjusted profit of $1.26 a share against analysts’ estimateof $1.21. This was Valeant’s first beat in a long time. Even on the revenue front, the company reported better than expected results. Initially, the stock gained on the report of an earnings beat. However, once the guidance figures came in, the stock tanked. In our earnings preview of Valeant, we had said that the adjusted EBITDA guidance for 2017 will be the key driver of VRX stock after the earnings.
- [By Kumar Abhishek]
2017 has turned out to be a good year for Valeant Pharmaceuticals Intl Inc(NYSE:VRX) so far. Shares of thespecialty pharma company have been on atear of late. Valeant stock has gained more than 25% since the end of January compared to over 3% gain in Nasdaq Composite (INDX:COMPX). The stock has gained more than 10% in the last two days. Valeant stock is up another 5% in the pre-market trade today on the news that FDA has approved “Siliq” (orbrodalumab as it was previously known), a drug marketed by Valeant to treat adults with moderate-to-severe plaque psoriasis.
- [By Ashley Moore]
This next company to short continues to make headlines for its purportedly illegal business practices…
Stocks to Short No. 2: Valeant Pharmaceuticals International Inc. (NYSE: VRX)
Valeant Pharmaceuticals International Inc. (NYSE: VRX) is known for its questionable business practices. The company is notorious for buying smaller pharmaceutical companies (financed with debt), firing the staff of the newly acquired company, and dramatically raising prices of the new drugs at its disposal.